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Summary. Results obtained in randomized trials may not easily generalize to target populations.
Whereas in randomized trials the treatment assignment mechanism is known, the sampling
mechanism by which individuals are selected to participate in the trial is typically not known
and assuming random sampling from the target population is often dubious. We consider an
inverse probability of sampling weighted (IPSW) estimator for generalizing trial results to a
target population. The IPSW estimator is shown to be consistent and asymptotically normal.
A consistent sandwich-type variance estimator is derived and simulation results are presented
comparing the IPSW estimator with a previously proposed stratified estimator.The methods are
then utilized to generalize results from two randomized trials of human immunodeficiency virus
treatment to all people living with the disease in the USA.
Keywords: Causal inference; External validity–generalizability; Human immunodeficiency
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1. Introduction
Generalizability is a concern for many scientific studies, including those in public health and
medicine (Cole and Stuart, 2010; Hernan and VanderWeele, 2011; Stuart et al., 2011, 2015;
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Tipton, 2013; Keiding and Louis, 2016) and economics (Hotz et al., 2005; Heckman et al.,
2006; Allcott, 2011, 2015; Allcott and Mullainathan, 2012; Hartman et al., 2015; Muller, 2014;
Gechter, 2015). Using information in the study sample, it is often of interest to draw inference
about a specified target population. Therefore, it is important to consider the degree to which
an effect estimated from a study sample approximates the true effect in the target population.
Unfortunately, study participants often do not constitute a random sample from the target pop-
ulation, bringing into question the generalizability of effect estimates based on such studies. For
example, in clinical trials of treatment for individuals who are infected with the human immun-
odeficiency virus (HIV), there is often concern that trial participants are not representative of
the larger population of HIV positive individuals. Greenblatt (2011) highlighted the overrep-
resentation of African-American and Hispanic women among HIV cases in the USA and the
limited clinical trial participation of members of these groups. The Women’s Interagency HIV
Study (WIHS) is a prospective, observational, multicentre study considered to be representative
of women living with HIV and women at risk for HIV infection in the USA (Bacon et al., 2005).
However, a review of eligibility criteria of 20 AIDS Clinical Trials Group (ACTG) studies found
that 28–68% of the HIV positive women in the WIHS cohort would have been excluded from
these trials (Gandhi et al., 2005).
There are several quantitative methods that provide a formal approach to generalize results
from a randomized trial to a specified target population. Some of these methods utilize a model
of the probability of trial participation conditional on covariates. Herein, we refer to this condi-
tional probability as the sampling score. Generalizability methods employing sampling scores
are akin to methods that use treatment propensity scores to adjust for (measured) confounding
(Rosenbaum and Rubin, 1983) and include the use of inverse probability of sampling weights
and stratification based on sampling scores. For example, Cole and Stuart (2010) estimated
sampling scores by using logistic regression and then employed inverse probability of sampling
weighted (IPSW) methods to estimate the treatment effect in the target population. The IPSW
approach is similar to inverse probability weighting methods that are used in a wide variety of
contexts (for example, see Wooldridge (2002), Ding and Lehrer (2010) and Seaman and White
(2013)). Another approach to generalizing trial results entails an estimator based on stratifying
individuals according to their estimated sampling scores (Tipton, 2013; O’Muircheartaigh and
Hedges, 2014; Tipton et al., 2014). To date, there have been no formal studies or derivations
of the large sample statistical properties (e.g. consistency and asymptotic normality) of these
generalizability estimators.
Following Cole and Stuart (2010) and Stuart et al. (2011), we consider an inverse weighting
approach based on sampling scores to generalize trial effect estimates to a target population. The
inverse-weighted estimator is compared with the stratified estimator. In Section 2, assumptions
and notation are discussed. The IPSW estimator and the stratified estimator are described in
Section 3.1. Large sample properties of the IPSW estimator are derived, including a closed
form expression for the asymptotic variance and a consistent sandwich-type estimator of the
variance. The finite sample performance of the IPSW and stratified estimators are compared
in a simulation study presented in Section 4. In Section 5, the IPSW estimator is applied to
generalize results from two ACTG trials to all people currently living with HIV in the USA.
Section 6 concludes with a discussion.
2. Assumptions and notation
Suppose that we are interested in drawing inference about the effect of a treatment (e.g. a drug)
on an outcome (e.g. a disease) in some target population. Assume that each individual in the
target population has two potential outcomes Y0 and Y1, where Y0 is the outcome that would
have been seen if (possibly contrary to fact) the individual received control, and Y1 is the outcome
that would have been seen if (possibly contrary to fact) the individual received treatment. Let
μ1 =E.Y1/ and μ0 =E.Y0/ denote the mean potential outcomes in the target population. The
parameter of interest is the population average treatment effect (PATE) Δ=μ1 −μ0. The goal is
to draw inference about Δ in a setting where two data sets are available. Assume that a random
sample (e.g. a cohort study) of m individuals is drawn from the target population. A second
sample of n individuals participate in a randomized trial. Unlike the cohort study, the trial
participants are not necessarily assumed to be a random sample from the target population but
rather may be a biased sample.
Throughout, it is supposed that the stable unit treatment value assumption (Rubin, 1980)
holds, i.e. there are no variations of treatment and there is no interference between individ-
uals. Under this assumption, each individual has only two potential outcomes: Y0 and Y1.
Plausibility of the assumption that there are no variations of treatment will depend on the
extent to which the form of treatment (i.e. the delivery mechanism, dose, non-compliance
rate and so forth) differs between individuals, in particular between trial and cohort study
participants. For example, in a randomized trial, treatment administration may be accom-
panied by adherence counselling, unlike in a cohort study. Note that the no variations of
treatment assumption applies both to the treatment as well as to the control condition, and
this would be suspect if there were a placebo effect in the randomized trial but not in the
cohort study. The no-interference assumption supposes that the treatment of one individ-
ual does not affect the outcome of any other individuals. This assumption will be plausi-
ble in many settings but may be questionable in some studies, e.g., in an influenza vaccine
trial, whether one individual is vaccinated may affect whether another individual develops
flu.
Suppose that the following random variables are observed for the cohort and trial participants.
Let Z be a 1×p vector of covariates and assume that information on Z is available for those in
the trial and those in the cohort. Let S = 1 denote trial participation and S = 0 otherwise. For
those individuals who participate in the trial, define X as the treatment indicator, where X=1
if assigned to treatment and X = 0 otherwise. Let Y = Y1X + Y0.1 − X/ denote the observed
outcome. Assume that .S, Z/ is observed for cohort participants and .S, Z, X, Y/ is observed for
trial participants.
Assume that the trial participants are randomly assigned to receive treatment or not such that
the treatment assignment mechanism is ignorable, i.e. P.X=x|S =1, Z, Y0, Y1/=P.X=x|S =1/.
Assume an ignorable trial participation mechanism conditional on Z, i.e. P.S = s|Z, Y0, Y1/=
P.S = s|Z/. In other words, participants in the trial are no different from non-participants
regarding the treatment–outcome relationship conditional on Z. The set of covariates Z
should be chosen such that the ignorable trial participation mechanism is considered plau-
sible. Judging whether a set of covariates Z is sufficient to satisfy this conditional independence
assumption may be facilitated by explicitly representing the assumed data-generating mecha-
nism using a directed acyclic graph (Greenland et al., 1999). The ignorable trial participation
mechanism assumption can then be verified by inspection of the directed acyclic graph (Pearl
and Bareinboim, 2014).
Trial participation and treatment positivity (Westreich and Cole, 2010) are also assumed, i.e.
P.S = 1|Z = z/ > 0 for all z such that P.Z = z/ > 0 and P.X = x|S = 1/ > 0 for x = 0, 1. That is,
there is a positive probability of being included in the trial for each value of the covariates.
Finally, it is assumed that the sampling score model, described in the next section, is correctly
specified.
3. Inference about the population average treatment effects
3.1. Estimators
A traditional approach to estimating treatment effects is a difference in outcome means between
the two randomized arms of the trial. Let i=1, : : : , n+m index the trial and cohort participants.















where here and in what follows Σi = Σn+mi=1 . If trial participants are assumed to constitute a
random sample from the target population, it is straightforward to show that Δ̂T is a consistent
and asymptotically normal estimator of Δ. In contrast, if we are not willing to assume that trial
participants are a random sample from the target population, then Δ̂T is no longer guaranteed
to be consistent.
Below we consider two estimators of Δ that do not assume that trial participants are a
random sample from the target population. Both estimators utilize sampling scores. Following
Cole and Stuart (2010), assume a logistic regression model for the sampling scores such that
P.S = 1|Z = z/ = {1 + exp.−zβ/}−1 where β is a p × 1 vector of coefficient parameters. Note
here and throughout that we assume that the 1 ×p vector Z includes 1 as the first component
to accommodate an intercept term in the sampling score model. Let β̂ denote the weighted
maximum likelihood estimator of β where each trial participant has weight Π−1Si = 1 and each
individual in the cohort has weight Π−1Si =m=.N −n/, where N is the size of the target population
(Scott and Wild, 1986). Let P.S =1|Z=z/=w.z,β/, wi =w.Zi,β/ and ŵi =w.Zi, β̂/. The IPSW
estimator (Cole and Stuart, 2010) of the PATE is














Another approach for estimating the PATE uses stratification based on the sampling scores
(Tipton, 2013; O’Muircheartaigh and Hedges, 2013; Tipton et al., 2014) and is computed in the
following steps. First, β is estimated by using a logistic regression model as described above and
the estimated sampling scores ŵi are computed. These estimated sampling scores are used to
form L strata. The difference of sample means within each stratum is computed among those in
the trial. The PATE is then estimated as a weighted sum of the differences of sample means across
strata. The stratum-specific weights used in computing this weighted average equal estimates
of the proportion of individuals in the target population within the stratum. Specifically, let nl
be the number of individuals in the trial in stratum l and ml be the number of individuals in
the cohort in stratum l. Let Sil = 1 denote trial participation for individual i in stratum l for
i = 1, : : : , nl + ml and l = 1, : : : , L (and Sil = 0 otherwise). If Sil = 1, then let Xil and Yil denote
the treatment assignment and outcome for individual i in stratum l; otherwise, if Sil = 0, then























where ωl =Nl=N, Nl =Σnl+mli=1 Π−1Sil and ΠSil is the weight for individual i in stratum l.
3.2. Large sample properties of the inverse probability of sampling weighted estimator
Because the trial participants are not assumed to be a random sample from the target popu-
lation, the observed random variables .Si, Zi, SiXi, SiYi/ for i= 1, : : : , n+m are assumed to be
independent but not necessarily identically distributed. Below, the IPSW estimator is expressed
as the solution to an unbiased estimating equation to establish asymptotic normality and to
provide a consistent sandwich-type estimator of the variance.
First, consider the case when β is known. Let θ̂Æ = .μ̂1, μ̂0/, θÅ = .μ1,μ0/ and note that θ̂Å is
the solution for θÅ of the estimating equation
∑
i


























cov{ΨÅΔ.Yi, Zi, Xi, Si, θÅ/}:
Define A.θÅ/= limm,n→∞ Am,n.θÅ/ and B.θÅ/= limm,n→∞ Bm,n.θÅ/. Note that E{ΨÅΔ.Yi, Zi, Xi,
Si, θÅ/}= 0 for i= 1, : : : , n+m, implying under suitable regularity conditions as n, m→∞ θ̂Æ
converges in probability to θÅ and .n + m/1=2.θ̂Æ − θÅ/ converges in distribution to N.0, ΣÅθ /
where
ΣÅθ =A.θÅ/−1B.θÅ/A.θÅ/−T .2/
(Carroll et al. (2010), appendix A.6). By Slutsky’s theorem and the delta method, Δ̂IPSW is a
consistent estimator of Δ and .n+m/1=2.Δ̂IPSW −Δ/ converges in distribution to N.0, ΣÅIPSW/
where
ΣÅIPSW =ΣÅ.11/θ +ΣÅ.22/θ −2ΣÅ.12/θ .3/
and in general Σ.ij/ refers to the entry in the ith row and the jth column of the matrix Σ. A
consistent estimator of equation (3) is given in the on-line appendix A.
Next consider the more likely case that β is unknown. Using weighted maximum likelihood,












(Scott and Wild, 1986). Let θ̂= .μ̂1, μ̂0, β̂/ and θ= .μ1,μ0,β/ and note that θ̂ is the solution for
θ of the .p+2/×1 vector estimating equation
∑
i


























cov{ΨΔ.Yi, Zi, Xi, Si, θ/}:
Define A.θ/ = limm,n→∞ Am,n.θ/ and B.θ/ = limm,n→∞ Bm,n.θ/. Note that E{ΨΔ.Yi, Zi, Xi,
Si, θ/}=0 for i=1, : : : , n+m, implying under suitable regularity conditions that, as n, m→∞,
θ̂ converges in probability to θ and .n+m/1=2.θ̂−θ/ converges in distribution to N.0, Σθ/ where
Σθ =A.θ/−1B.θ/A.θ/−T .4/
(Carroll et al., 2010). By Slutsky’s theorem and the delta method, Δ̂IPSW is a consistent estimator
of Δ and .n+m/1=2.Δ̂IPSW −Δ/ converges in distribution to N.0, ΣIPSW/ where
ΣIPSW =Σ.11/θ +Σ.22/θ −2Σ.12/θ : .5/
A consistent estimator of equation (5) is given in the on-line appendix A. This variance estimator
can be used to construct Wald-type confidence intervals (CIs) for Δ.
A comparison of equations (3) and (5) shows that the variance is smaller when the sampling
scores are estimated (see the on-line appendix B). Therefore, even if the correct sampling scores
are known, estimation of the sampling scores is preferable because of improved efficiency. This
is analogous to a well-known result for inverse-treatment-weighted estimators (Hirano et al.,
2003; Robins et al., 1992; Wooldridge, 2007). In general, it is common practice to compute the
variance of the inverse-probability-weighted estimators by using standard software assuming
that the weights are known. This leads to valid but conservative CIs. In the on-line supplementary
materials, an R function is provided which computes the IPSW estimator and the corresponding
(consistent) sandwich-type estimator of the variance described in appendix A which does not
assume that β is known.
3.3. Estimator of the variance of the stratified estimator
One approach to obtain an estimator of the variance of the stratified estimator is to express Δ̂S as
the solution to an unbiased vector of estimating equations, which include an estimating equation
for the potential outcome means, the L quantiles and each element of β. This approach can be
used to show that Δ̂S is asymptotically normal (Lunceford and Davidian, 2004). In practice, it
is routine to approximate the sampling variance of Δ̂S by treating the estimator as the average
of L independent, within-stratum, treatment effect estimators (Tipton, 2013; Lunceford and






where σ̂2l = Σ1x=0n−1xl s2xl, nxl = Σnl+mli=1 SilI.Xil = x/, sxl = n−1xl Σnl+mli=1 SilI.Xil = x/.Yil − Ȳxl/2 and
Ȳxl =n−1xl Σnl+mli=1 SilI.Xil =x/Yil for x=0, 1.
4. Simulations
A simulation study was conducted to compare the performance of the IPSW and stratified
estimators in scenarios with a continuous or discrete covariate and a continuous outcome. The
following quantities were computed for each scenario: the bias for each estimator, the average
of the estimated standard errors, empirical standard error and empirical coverage probability
of the 95% CIs.
A total of 5000 data sets were simulated per scenario as follows. There were N = 106 obser-
vations in the target population with sample score wi = {1 + exp.−β0 −β1Z1i/}−1. In the first
two scenarios, one binary covariate Z1i ∼Bernoulli.0:2/ was considered and, for scenarios 3–6,
one continuous covariate Z1i ∼ N.0, 1/ was considered. The covariate Z1i was associated with
trial participation and a treatment effect modifier. A Bernoulli trial participation indicator Si
was simulated according to the true sampling score wi in the target population and those with
Si = 1 were included in the trial. The parameters β0 and β1 were set such that the sample size
in the trial was approximately n ≈ 1000. The cohort was a random sample of size m = 4000
from the target population (less those selected in the trial). The number of participants in the
randomized trial was small compared with the size of the target, so the cohort was essentially
a random sample from the target.
For those who were included in the randomized trial (Si = 1), Xi was generated as Bernoul-
li(0.5) and the outcome Y was generated according to Yi =ν0 +ν1Z1i + ξXi +αZ1iXi + εi, εi ∼
N.0, 1/. For scenarios 1–4, .ν0, ν1, ξ,α/ = .0, 1, 2, 1/. For scenarios 5 and 6, .ν0, ν1, ξ,α/ =
.0, 1, 2, 2/. Two sampling score models were considered: β= .−7, 0:4/ for scenarios 1, 3 and
5; β= .−7, 0:6/ for scenarios 2, 4 and 6. The truth was calculated for each scenario on the basis
of the distribution of Z1i in the target population. The truth was Δ=2:2 for scenarios 1 and 2
and Δ= 2 for scenarios 3–6. To estimate the sampling scores, the combined trial (Si = 1) and
cohort (Si =0) data were used to fit a (weighted) logistic regression model with Si as the outcome
and the covariate Z1i as described in Section 3.1.
Comparisons between the IPSW and stratified estimator when the sampling score model was
correctly specified are summarized in Table 1. The within-trial estimator Δ̂T was biased for
all scenarios and had low coverage (the results are not shown). For all scenarios, Δ̂IPSW was
unbiased. For scenarios 1 and 2, Δ̂S was unbiased and standard errors were comparable with
Δ̂IPSW. For scenarios 3–6, Δ̂S was biased, possibly because of residual confounding from a
continuous covariate in the sampling score model. For the IPSW estimator, the average of the
estimated standard error was approximately equal to the empirical standard error, supporting
the derivations of the sandwich-type estimator of the variance. For all scenarios, coverage was
approximately 95% for the Wald CI of Δ̂IPSW. With a continuous covariate, the Wald CI of the
Table 1. Simulation results for estimators of Δ when the sampling score model was correctly specified†
Scenario Covariate (β1,α) Bias Empirical Average Empirical
standard error estimated coverage
Δ̂T Δ̂S Δ̂IPSW (× 100) standard probability
error (× 100)
Δ̂S Δ̂IPSW Δ̂S Δ̂IPSW
Δ̂S Δ̂IPSW
1 Binary (0.4,1) 0.07 0.00 0.00 6.2 7.1 7.1 7.3 0.98 0.95
2 Binary (0.6,1) 0.11 0.00 0.00 6.3 7.1 6.6 7.1 0.96 0.95
3 Continuous (0.4,1) 0.20 0.04 0.00 8.1 13.4 7.9 13.4 0.91 0.95
4 Continuous (0.6,1) 0.60 0.07 0.00 8.6 15.0 8.6 14.9 0.88 0.95
5 Continuous (0.4,2) 0.80 0.09 0.00 9.4 17.2 8.9 17.2 0.81 0.95
6 Continuous (0.6,2) 1.20 0.14 0.00 10.1 19.9 9.8 19.6 0.70 0.95
†For 5000 simulated data sets with m= 4000 and n≈ 1000 per data set. The scenarios are described in Section 4.
For scenarios 1 and 2 Δ=2:2 and for scenarios 3–6 Δ=2:0. (T, within trial; S, stratified.)
stratified estimator had poor coverage, particularly in the presence of stronger effect modification
(e.g. scenarios 5 and 6). Histograms of the three estimators for scenario 4 are given in Fig. 1;
the IPSW was approximately unbiased and normally distributed.
Simulations were also performed with the sampling score model misspecified. A second co-
variate was generated for each member of the target population and the true sampling score was
wi ={1+exp.−β0 −β1Z1i −β2Z2i/}−1. For the first two scenarios, Z2i ∼Bernoulli.0:6/ and, for
scenarios 3–6, Z2i ∼N.0, 1/. For those included in the randomized trial (Si =1), Xi was generated
as Bernoulli.0:5/ and the outcome Y was generated according to Yi =ν0 +ν1Z1i +ν2Z2i +ξXi +
α1Z1iXi +α2Z2iXi + εi, εi ∼ N.0, 1/. For scenarios 1–4, .ν0, ν1, ν2, ξ,α1,α2/ = .0, 1, 1, 2, 1, 1/.
For scenarios 5 and 6, .ν0, ν1, ν2, ξ,α1,α2/= .0, 1, 1, 2, 2, 2/. The estimated sampling scores were
computed on the basis of a misspecified logistic regression with Z1i as the only covariate, i.e.
ŵi ={1+exp.−β̂0 − β̂1Z1i/}−1. Two sampling score models were considered: scenarios 1, 3 and
5 set β= .−7, 0:4, 0:4/; scenarios 2, 4 and 6 set β= .−7, 0:6, 0:6/. Based on the distribution of
Zi = .Z1i, Z2i/ in the target population, the truth was Δ= 2:8 for scenarios 1 and 2 and Δ= 2
for scenarios 3–6.
Comparisons between the IPSW and stratified estimators when the sampling score model
was misspecified are summarized in the on-line appendix C Table 1. The bias was reduced by
approximately half when either the IPSW or the stratified estimator was employed as compared
with the within-trial estimator. The sandwich-type estimator of the variance of the IPSW esti-
mator performed reasonably well when the sampling score model was misspecified; however, CI
coverage was below the nominal level.
Lastly, simulations were also performed with reduced overlap in the distribution of Z in the
trial and target population. Specifically, the simulation study that was described above with
correct specification of the sampling score model was repeated, except that β1 = 1 in scenarios
1, 3 and 5, and β1 = 2 in scenarios 2, 4 and 6. Thus, there was a stronger association between
the covariate Z1 and trial participation than in the original set of simulations, leading to greater
differences in the covariate distributions between trial participants and the cohort. For example,
in scenario 1, P.Z1 = 1|S = 1/ = 0:40 and P.Z1 = 1|S = 0/ = 0:20 when β1 = 1, compared with
P.Z1 =1|S =1/=0:26 and P.Z1 =1|S =0/=0:20 when β1 =0:4. Results from this last simula-
tion study are summarized in the on-line appendix C Table 2. The IPSW estimator was unbiased
for all scenarios, with the corresponding CI coverage approximating the nominal level except in
scenarios 4 and 6. The stratified estimator was biased (although less than the within-trial estima-
tor) and the corresponding CIs did not cover at the nominal level except in scenario 1. Because
of the reduced overlap in the covariate distributions between the trial and cohort, both the IPSW
and the stratified estimators were more variable relative to the simulation results in Table 1.
5. Applications
5.1. Trials and cohorts
In this section, the methods that were described in Section 3.1 are applied to generalize results
from two different ACTG randomized clinical trials: ACTG 320 and ACTG A5202. Two differ-
ent target populations are considered, namely all women currently living with HIV in the USA
and all people currently living with HIV in the USA.
The ACTG 320 trial examined the safety and efficacy of adding a protease inhibitor (PI) to
an HIV treatment regimen with two nucleoside analogues. A total of 1156 participants were
enrolled in the ACTG 320 trial between January 1996 and January 1997 and were recruited
from 33 acquired immune deficiency syndrome (AIDS) clinical trial units and seven National











































































































































































and highly active anti-retroviral therapy (HAART) naive, and had CD4 T-cell counts of 200
cells mm−3 or fewer at screening. Of the 1156 participants, 200 were women (Hammer et al.,
1997). Among ACTG 320 trial participants, 116 (10%) were missing the outcome of CD4 cell
count at week 4, so they were excluded from the analysis below. The baseline characteristics of
the ACTG 320 trial participants are shown in Table 2.
The ACTG A5202 trial assessed equivalence of abacavir–lamivudine (known as ‘ABC–3TC’)
or tenofovir disoproxil fumarate–emtricitabine (known as ‘TDF–FTC’) plus efavirenz or riton-
avir-boosted atazanavir. A total of 1857 participants were enrolled in trial A5202 between
September 2005 and November 2007 and were recruited from 59 ACTG sites in the USA and
Puerto Rico. These participants were HIV positive and anti-retroviral (ART) naive and had a
viral load greater than 1000 copies ml−1 at screening. Of the 1857 participants, 322 were women
(Sax et al., 2009, 2011). Among A5202 trial participants, 417 (22%) were missing the outcome
of CD4 cell count at week 48, so they were excluded from the analysis below. The baseline
characteristics of the A5202 trial participants are shown in Table 3.
Data from two cohort studies, the WIHS and Center for AIDS Research (CFAR) Network
of Integrated Clinical Systems (known as the ‘CNICS’), are used in the analysis below to gener-
alize the ACTG 320 and A5202 trial results. Participants in the WIHS and CNICS study were
considered to be representative samples of the target populations, i.e. all women living with
HIV in the USA and all people living with HIV in the USA respectively. A total of 4129 women
(1065 HIV uninfected) were enrolled in the WIHS between October 1994 and December 2012
Table 2. Characteristics of WIHS participants, CNICS study participants and ACTG 320 trial participants
at baseline†
Variable Results for Results for Results for Results for
WIHS ACTG 320 women CNICS study ACTG 320 men
(m=493) (n=200) (m=6158) and women
(n=1156)
Male sex .%/ 0 0 80 83
Race or ethnic group .%/
White, non-Hispanic 18 31 40 52
Black, non-Hispanic 55 48 44 28
Hispanic 25 21 12 18
Asian or other 2 1 5 2
Median age (years) 40 (35–45) 36 (30–42) 41 (34–47) 38 (33–44)
(quartile 1–quartile 3)‡
Age group .%/
[16, 30/ years 7 23 12 12
[30, 40/ years 43 44 34 47
[40, 50/ years 40 27 37 30
[50, ·/ years 10 7 17 11
Injection drug use (%) 37 18 20 16
Median CD4 cell count‡ 108 (41–172) 82 (26–139) 89 (27–172) 75 (23–137)
(quartile 1–quartile 3)
Baseline CD4 cell count .%/
.0, 50/ cells mm−3 30 36 36 39
[50, 100/ cells mm−3 17 22 17 22
[100, 200/ cells mm−3 37 37 30 32
[200, ·/ cells mm−3 16 6 17 7
†m is the number of participants in the cohort study. n is the number of participants in the trial.
‡One ACTG 320 trial participant was missing a CD4 cell count.
Table 3. Characteristics of WIHS participants, CNICS study participants and ACTG A5202 trial participants
at baseline†
Variable Results for Results for Results for Results for
WIHS ACTG A5202 CNICS study ACTG A5202 men
(m=1012) women (m=12302) and women
(n=322) (n=1857)
Male sex .%/ 0 0 82 83
Race or ethnic group‡ (%)
White, non-Hispanic 17 18 45 40
Black, non-Hispanic 58 53 38 33
Hispanic 22 26 12 23
Asian or other 3 3 5 3
Median age (years) 39 (33–44) 39 (31–46) 39 (31–46) 38 (31–45)
(quartile 1–quartile 3)
Age group .%/
[16, 30/ years 12 18 20 22
[30, 40/ years 43 34 34 34
[40, 50/ years 34 33 32 31
[50, ·/ years 11 15 14 14
Injection drug use (%) 38 6 17 9
Hepatitis B or C .%/ 35 8 18 9
AIDS diagnosis .%/ 37 19 23 17
CD4 cell count§ .%/
.0, 50/ cells mm−3 10 19 16 18
[50, 100/ cells mm−3 6 7 7 8
[100, 200/ cells mm−3 16 17 14 17
[200, 350/ cells mm−3 29 40 27 35
[350, ·/ cells mm−3 39 16 36 22
Median CD4 cell count 290 (162–423) 226 (87–313) 271 (109–427) 230 (90–334)
(quartile 1–quartile 3)
Viral load (%)
[0, 50000/ copies ml−1 55 58 52 54
[50000, 100000/ copies ml−1 14 19 15 21
[100000, 300000/ copies ml−1 19 12 18 11
[300000, 500000/ copies ml−1 5 3 6 4
[500000, ·/ copies ml−1 7 8 8 10
Median log10 viral load 4.61 (4.04–5.11) 4.58 (4.07–4.93) 4.64 (3.95–5.18) 4.66 (4.33–5.01)
(quartile 1–quartile 3)
†m is the number of participants in the cohort study. n is the number of participants in the trial.
‡Five A5202 trial participants were missing race.
§One A5202 trial participant was missing a CD4 cell count.
at six US sites (Bacon et al., 2005). The CNICS study captures comprehensive and standardized
clinical data from point-of-care electronic medical record systems for population-based HIV
research (Kitahata et al., 2008). The CNICS cohort includes over 27000 HIV-infected adults
(at least 18 years of age) engaged in clinical care since January 1995 at eight CFAR sites in the
USA.
For generalizing results from the ACTG 320 trial, the analysis included cohort participants
who were HIV positive and HAART naive, and had CD4 cell counts of 200 cells mm−3 or
fewer at the previous visit (m = 493 women and m = 6158 men and women combined). For
generalizing results from the A5202 trial, the analysis included cohort participants who were
HIV positive and ART naive, and had a viral load of 1000 copies ml−1 at the previous visit (m=
1012 women and m= 12302 men and women combined). Table 2 displays the characteristics of
the women in the WIHS sample and the participants in the CNICS sample that were used to
generalize results from the ACTG 320 trial. Likewise, the characteristics of the women in the
WIHS sample and participants in the CNICS sample that were used to generalize results from
the ACTG A5202 trial are displayed in Table 3.
5.2. Analysis
The IPSW and stratified estimators were employed to generalize the difference in the average
change in CD4 cell count from baseline between treatment groups observed among women in
the trials to all women currently living with HIV in the USA and among all participants in the
trials to all people currently living with HIV in the USA. On the basis of Centers for Disease
Control and Prevention (2012) estimates, the size of the first target population was assumed to
be 280000 women and the size of the second target population was assumed to be 1.1 million
people.
The PATE was estimated by using the IPSW estimator in equation (1). To estimate the sam-
pling scores, the data from the ACTG trial (i.e. 320 and A5202) and cohort (i.e. WIHS or
CNICS) were analysed together, with S = 1 for those in the ACTG trial and S = 0 for those in
the cohort. In the model to estimate the sampling scores, the outcome was trial participation
and the possible covariates for the ACTG 320 trial included sex, race or ethnicity, age, history of
injection drug use (IDU) and baseline CD4 cell count, and for the ACTG A5202 trial included
sex, race or ethnicity, age, history of IDU, hepatitis B or C, AIDS diagnosis, baseline CD4 cell
count and baseline log10 viral load. The variable hepatitis B or C was binary, indicating infec-
tion with hepatitis B or hepatitis C or both. Variables associated with trial participation, the
outcome, or effect modifiers, as well as all pairwise interactions, were included in the sampling
score model. Sex was not included as a covariate in analyses generalizing the trial results among
women.
5.3. Results
Estimates of the mean differences based on the within-trial estimator among women and all
participants are given in Table 4. Among all participants and among just women in the ACTG
320 trial, there was a significant difference in the change in CD4 cell count from baseline to
4 weeks between the PI and non-PI groups. Among women in the A5202 trial at week 48, those
randomized to ABC–3TC had an average change in CD4 cell count that was comparable with
those randomized to a regimen with TDF–FTC. Among all participants in the A5202 trial,
those randomized to ABC–3TC had an average change in CD4 cell count that was slightly
higher than those randomized to a regimen with TDF–FTC, but this did not achieve statistical
significance.
Table 4 also displays the results for the two ACTG trials generalized to both target populations.
In the target population of all women living with HIV in the USA, the IPSW estimate was
approximately double the within-trial estimate (Δ̂IPSW =46 compared with Δ̂T =24), suggesting
that the within-trial result may underestimate the effects of PIs in all HIV-infected women in
the USA. The IPSW estimator also indicated a much stronger protective effect of ABC–3TC
(versus TDF–FTC) in the target population of all HIV-infected women in the USA (Δ̂IPSW =35
compared with Δ̂T =1), providing evidence that this particular ART combination may increase
CD4 cell counts more on average than what was observed in the trial. In the target population of
all people living with HIV in the USA, the IPSW estimates were comparable with the within-trial
effect estimates, suggesting that both the effect of PIs and the effect of the ART combination
ABC–3TC (versus TDF–FTC) from the trials may be generalizable to all people living with HIV
Table 4. Estimated difference in mean change in CD4 cell count and corresponding 95%
CIs in two target populations (all men and women combined and all women living with HIV in 
the USA) based on data from ACTG trials, the WIHS and CNICS†
Cohort m Trial n Difference in mean change (95% CI)
Δ̂T Δ̂S Δ̂IPSW
WIHS 493 ACTG 320‡ 200 24 (7, 41) 38 (17, 59) 46 (23, 70)
WIHS 1012 ACTG A5202§ 322 1 (−35, 37) −19 (−62, 25) 35 (−45, 115)
CNICS 6158 ACTG 320 1156 19 (12, 25) 18 (9, 26) 17 (9, 25)
CNICS 12302 ACTG A5202 1857 6 (−8, 20) 7 (−18, 32) −2 (−31, 28)
†For the ACTG 320 trial, the outcome was change in CD4 cell count from baseline to week 4.
For the A5202 trial, the outcome was change in CD4 cell count from baseline to week 48.
‡For the ACTG 320 trial, the treatment contrast was PI (X=1) versus no PI (X=0).
§For the A5202 trial, the treatment contrast was ABC–3TC (X=1) versus TDF–FTC (X=0) plus
efavirenz or ritonavir-boosted atazanavir.
in the USA. In summary, these results suggest that the ACTG trial results are more generalizable
for US men with HIV than US women with HIV.
6. Discussion
In this paper, we considered generalizing results from a randomized trial to a specific target
population by using inverse probability of sampling weights. The IPSW estimator was shown
to be consistent and asymptotically normal and a consistent sandwich-type estimator of the
variance was provided. In a simulation study, the IPSW estimator outperformed the stratified
estimator when the sampling score was correctly specified. The IPSW estimator was unbiased
for all scenarios and the CIs exhibited coverage that was approximately at the nominal level,
except when there was limited overlap in the distribution of covariates in the trial compared
with the target population. With a continuous covariate, the stratified estimator exhibited bias
and the corresponding CI had poor coverage, particularly in the presence of stronger effect
modification.
In the illustrative example, the ACTG 320 and A5202 trial results appear to be generalizable to
all people living with HIV in the USA. In contrast, the within-trial effect estimates among women
in the two ACTG trials were not comparable with the effect estimates in the target population of
women. This lack of comparability may be explained by differences in the distribution of certain
effect modifiers between the trial and the target population. Figs 1–4 in the on-line appendix
D show within-trial subgroup effect estimates and CIs for both trials. Among women in the
A5202 trial, the results in Fig. 3 of appendix D suggest that hepatitis B or C, IDU and age were
possible effect modifiers. These three covariates were also associated with trial participation
among women, and thus may explain why the A5202 within-trial effect estimate among women
was not similar to the IPSW effect estimate in the target population of women. In particular,
women with hepatitis B or C were less likely to participate in the A5202 trial and tended to have
a greater mean change in CD4 cell count. Thus, by accounting for hepatitis B or C, we would
expect the IPSW estimate to be greater than the within-trial estimate. Likewise, women who
were younger or had a history of IDU were also less likely to participate in the A5202 trial and
tended to have a greater mean change in CD4 cell count than older women or those without a
history of IDU respectively. Results from both the ACTG A5202 and the ACTG 320 trial were
not sensitive to the specification of the size of the target population, although some results were
sensitive to the specification of the sampling score model (the results are not shown). In the
data example, a complete-case analysis was performed; however, in practice, one would want
to address the possibility that the missingness was not completely at random.
When applying these methods, the analysis is subject to the following considerations. First,
the ignorable trial participation mechanism is a key assumption which supposes that partic-
ipants in the ACTG trials are no different from individuals in the WIHS and the CNICS
study with respect to the treatment–outcome relationship conditional on observed covariates.
However, it is plausible that there are unmeasured covariates that are associated with trial
participation and the outcome which confound the association between treatment and out-
come even after conditioning on the observed covariates. The methods considered in this paper
also assume that there are no variations in treatment. Within the context of the HIV treat-
ment trial analysis, this assumption supposes that ART adherence rates were similar between
those in the target population and participants in the ACTG trials. This assumption could
be assessed if data related to adherence had been collected in the WIHS, the CNICS study
and the ACTG trials. The no variations of treatment assumption additionally supposes that
there are no other behavioural responses or contextual effects (Ding and Lehrer, 2015) of
study participation that would not remain if the treatment were adopted in the target popu-
lation.
In addition, the sampling score model was assumed to be correctly specified (e.g. correct
covariate functional forms). Because some degree of model misspecification is inevitable, a
sensitivity analysis of inferences about the treatment effect in the population to the sampling
score model specification is recommended. Similarly, the stratified estimator (Tipton et al.,
2014; O’Muircheartaigh and Hedges, 2013) requires that individuals sharing the same stratum
of the sampling score distribution can be identified. This estimator may be biased when there
is residual confounding within strata and, in general, is not a consistent estimator of the PATE
(Lunceford and Davidian, 2004).
The inferential methods considered in this paper assume that the cohort is a random sample
(i.e. representative) of the target population. In the HIV application, participants in the WIHS
(or CNICS study) are assumed to constitute a random sample of women (men and women)
living with HIV in the USA. This assumption would be violated if cohort participation is
associated with individual characteristics, such as age, living in an urban area, income and
employment status. In the context of the HIV application, this assumption might be considered
more plausible if the target population were instead defined with greater specificity, e.g. as all
women (and men) living with HIV who are in care at the geographical locations which have sites
in the cohort studies. If the cohort is not considered representative of the target population,
one possibility is weighting the cohort data to the distribution of covariates in a census (e.g.
Centers for Disease Control and Prevention estimates). A limitation of this approach is that the
census may not have covariate information as rich as the cohort data. The Centers for Disease
Control and Prevention estimates that were used to quantify the size of the target population
in the example were for all people living with HIV. Use of surveillance studies that report on
the number of ART and HAART naive HIV patients in the USA could further sharpen the
information about the target population.
In this paper, we consider randomized trials where individuals are independently randomized
to treatment or control. Future research could entail extensions to cluster randomized trials
wherein clusters of individuals are independently randomized to treatment or control, with all
individuals in the same cluster receiving the same randomization assignment. Causal inference
methods for individually randomized studies are not necessarily valid for cluster randomized
trials (Middleton and Aronow, 2015), such that the methods that are considered in this paper
may not be directly applicable to cluster randomized trials.
Future research could also entail the use of machine learning methods (Westreich et al., 2010),
maximum entropy (Hartman et al., 2015) or flexible regression methods such as Bayesian adap-
tive tree regression (Chipman et al., 2010) instead of weighted logistic regression to estimate
the sampling scores. The IPSW estimator considered in this paper may be highly variable when
there is limited overlap in the distribution of the covariates in the trial compared with the tar-
get population. Thus, alternative estimators should be developed for settings where there is
limited covariate distribution overlap. Formal sensitivity analysis methods could be developed
to assess the extent to which violations of key assumptions, such as the ignorable trial partic-
ipation mechanism assumption, potentially affect inference about the treatment effect in the
target population. Alternatively, bounds could be derived (as in Gechter (2015)) under weaker
assumptions which only partially identify the PATE. For the methods that were considered in
this paper, no information on the exposure or outcome is required from the cohort study. In
settings where the outcome data are available in the cohort, approaches similar to Hotz et al.
(2005) and Hartman et al. (2015) could be developed to test the ignorable trial participation
mechanism assumption.
Additional extensions might be considered based on the types of data that are typical of
biomedical, public health and econometric studies. For example, time-to-event end points are
common in HIV and AIDS trials, so extensions to accommodate right-censored outcomes
could be considered. Lastly, in some settings such as infectious disease studies, the treatment or
exposure of one individual may affect the outcome of another individual; extensions of existing
generalizability methods, such as using inverse probability of sampling weights, to allow for
interference would have utility in such settings.
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